

Special Issue

Research in Bat-Borne Zoonotic Viruses

Message from the Guest Editors

Bats are suggested to be important reservoir hosts of many zoonotic viruses that can cross species barriers to infect humans and other domestic or wild mammals, including lyssaviruses, henipaviruses, ebolaviruses, marburgviruses, and Mers and Sars-coronaviruses. A bat origin of the recent SARS-CoV-2 (2019-nCoV), responsible for COVID-19, which started in Wuhan (China) in December 2019, has also been hypothesized. It has been assumed that bats may have a “special” relationship with viruses based on physiological, ecological, evolutionary, and/or immunological aspects, which allow them to act as special reservoir hosts for a variety of viruses that lead to efficient pathogen maintenance, evolution, and spread. In this Special Issue, we invite you to submit research papers and reviews on a wide range of research topics related to Bat-Borne Zoonotic Viruses. Topics of interest include (but are not limited to) epidemiology, diagnosis, pathogenesis, vaccines, immunology, virome of bats, genetic and antigenic characterization, viral evolution, and phylogenetic studies.

Guest Editors

Dr. Davide Lelli

Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini", IZSLER. Via Bianchi, 9 - 25124 Brescia, Italy.

Dr. Ana Moreno

Virology Department, Istituto Zooprofilattico Sperimentale della Lombardia ed Emilia-Romagna, Via Bianchi 9, 25124 Brescia, Italy

Deadline for manuscript submissions

closed (30 September 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/42228

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).